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Lafora progressive myoclonous epilepsy (Lafora disease; LD)
is caused bymutations in theEPM2A gene encoding a dual spec-
ificity protein phosphatase named laforin. Our analyses on the
Epm2a gene knock-out mice, which developed most of the
symptoms of LD, reveal the presence of hyperphosphorylated
Tau protein (Ser396 and Ser202) as neurofibrillary tangles (NFTs)
in the brain. Intriguingly, NFTs were also observed in the skel-
etal muscle tissues of the knock-out mice. The hyperphospho-
rylation of Tau was associated with increased levels of the active
form of GSK3. The observations on Tau protein were repli-
cated in cell lines using laforin overexpression and knockdown
approaches. We also show here that laforin and Tau proteins
physically interact and that the interaction was limited to the
phosphatase domain of laforin. Finally, our in vitro and in vivo
assays demonstrate that laforin dephosphorylates Tau, and
therefore laforin is a novel Tau phosphatase. Taken together,
our study suggests that laforin is one of the critical regulators of
Tau protein, that the NFTs could underlie some of the symp-
toms seen in LD, and that laforin can contribute to the NFT
formation in Alzheimer disease and other tauopathies.
Lafora disease (LD)2 is an autosomal recessive and a fatal
form of progressive myoclonus epilepsy characterized by the
presence of Lafora polyglucosan bodies in the affected tissues
(1). The symptoms of LD include stimulus-sensitive epilepsy,
dementia, ataxia, and rapid neurologic deterioration (1, 2). LD
is caused by mutations in the EPM2A gene encoding laforin, a
dual specificity protein phosphatase, or in the NHLRC1 gene
encoding malin, an E3 ubiquitin ligase (3–7). Both laforin and
malin are ubiquitously expressed (3, 5), associated with the
endoplasmic reticulum (4, 7), form aggresome upon proteaso-
mal blockade (7), and clear misfolded protein through ubiq-
uitin-proteasome (8). Laforin has two functional domains: a
phosphatase domain (dual specificity phosphatase domain;
DSPD) and a carbohydrate binding domain (CBD) (9). The
CBD helps laforin to target to the glycogen particle and to the
Lafora bodies (9, 10), and theDSPDof laforin dephosphorylates
carbohydrate moieties (11). Recent studies have further shown
that laforin and malin together regulate the cellular levels of
PTG, the adaptor protein targeting to glycogen, and that the
loss of either malin or laforin results in increased levels of PTG
that eventually lead to excessive glycogen deposition (12–14).
Although this model explains the genesis of Lafora bodies, the
molecular etiology of LD is yet to be understood. For example,
unlike this cell line study (12), the presence of Lafora bodies
does not lead to neuronal cell death in the twomurinemodels of
LD (10, 15), and no difference in the level of PTG was seen in
laforin-deficient mice (16).3 However, widespread degenera-
tion of neurons was seen in laforin-deficient mouse with the
absence of Lafora bodies, suggesting that the polyglucosan bod-
ies may not play a primary role in the epileptogenesis (15). The
laforin dominant-negative transgenic mice line also developed
Lafora bodies but had no signs of neurodegeneration or epilep-
tic seizures (10). Thus, the neurodegenerative changes are likely
to underlie the etiology of some of the LD symptoms (1). The
mouse model developed by the knockdown of the Epm2a gene
exhibited a majority of the symptoms known in LD, including
the ataxia, spontaneous myoclonic seizures, EEG epileptiform
activity, and impaired behavioral responses (15). The knock-
out animals showed a number of degenerative changes that
include swelling and/or loss of morphological features of mito-
chondria, endoplasmic reticulum, Golgi apparatus, and the
neuronal processes (15). Preliminary histochemical investiga-
tions have also suggested the possible presence of neurofibril-
lary tangles (NFTs) in the knock-outmice (17). In this study, we
have characterized the biochemical properties of Tau protein in
the animal model of LD and identified laforin as an interacting
partner of Tau. Our study identifies laforin to be one of the
critical regulators of Tau protein and suggests that the Tau
pathology might underlie some of the symptoms seen in LD.
EXPERIMENTAL PROCEDURES
Mice and Tissue Harvesting—The characterization of
laforin-deficient mice has been described previously (15). The
animals were maintained at the RIKEN Brain Science Institute
animal facilities according to the Institute guidelines for the
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treatment of experimental animals. Animals of 4-, 6-, or
10-month-old age groups were sacrificed by cervical disloca-
tion, and selected tissues were dissected and fixed in appropri-
ate fixatives or quickly frozen in liquid nitrogen and stored at
80 °C until further analysis.
Tissue Extraction and Subcellular Fractionation—Brain and
muscle tissues were homogenized in Tris-buffered saline con-
taining protease and phosphatase inhibitors and used for
immunoblotting analysis. The Sarkosyl-soluble and -insoluble
fractions of NFTs were extracted as described (18).
Antibodies—The following monoclonal antibodies, obtained
as gifts from Dr. Peter Davies, were used for detecting the Tau
protein: CP13 for phospho-Ser202 Tau, PHF1 for phospho-
Ser396 Tau, andTGF5 for all forms of Tau. In addition, antibod-
ies from Innogenetics (antibody AT8) and GenScript for the
detection of phospho-Ser202 and an antibody from Epitomics
(antibody E178) for the detection of phospho-Ser396 were also
used. Antibodies for Gsk3, phospho-Ser9 Gsk3, protein
kinaseB (AKT), and Ser473 phospho-AKTwere purchased from
Cell Signaling Technology. Antibodies for protein phosphatase
2A (PP2A), Tyr307 phospho-PP2A, cyclin-dependent kinase 5
(CDK5), Ser159 phospho-CDK5, protein kinase A (PKA), Ser96
phospho-PKA, and PP1 were purchased from Santa Cruz Bio-
technology, Inc. (Santa Cruz, CA). Anti-GFP and anti-Myc tag
antibodies were purchased from Roche Applied Science, and
anti--tubulin, anti-FLAG, and anti-V5 antibodies were from
Sigma. Anti-ubiquitin antibody was purchased fromDako, and
the secondary antibodieswere obtained from Jackson Immuno-
Research. Anti-laforin antibody was raised in rabbits using a
synthetic peptide corresponding to amino acid residues 85–100
of the murine laforin sequence.
Immunohistochemical and Histopathological Analyses—
Immunohistochemical analysis was done on formalin-fixed,
paraffin-embedded sections and was reacted with appropriate
antibody, as described previously (8, 15). They were visualized
for light microscopy using diamino-benzidine-conjugated avi-
din-biotin complex kit (Vectastain ABC Elite; Vector Labora-
tories). For immunofluorescence staining, sections were pro-
cessed with appropriate secondary antibodies that were
conjugated with rhodamine or fluorescein isothiocyanate
and visualized using an epifluorescence microscope, as
described (8, 15). Bielschowsky’s silver staining was done on
paraffin embedded brains sections as described previously
(19).
Ultrastructural Analysis—For electron microscopy studies,
the Sarkosyl-insoluble materials, isolated from the laforin-defi-
cient mice, were mildly sonicated and dispersed in phosphate-
buffered saline. For negative staining, the samples were first
absorbed onto glow-discharged supporting membranes on
300-mesh grids and then treated with 2% uranyl acetate, dried,
and observed with a FEI Technai 20 U Twin electron micro-
scope. For immunogold labeling, the samples were prefixed by
floating the grids on drops of 4% paraformaldehyde in 0.1 M
phosphate buffer for 5 min. After washing, the grids were incu-
bated with primary antibody followed by 10-nm colloidal gold-
conjugated secondary antibody and processed for negative
staining with 2% sodium phosphotungstic acid and observed as
described (20).
Expression Constructs—The expression vectors containing
Myc- or GFP-tagged wild-type or mutant forms of laforin were
described previously (7, 8). Expression constructs for the
FLAG-tagged laforin were generated by cloning the coding
regions of the EPM2A gene into the pcDNA expression vector
(Invitrogen). The short hairpin RNAknockdown constructs for
the Epm2a gene were purchased from Open Biosystems and
validated in one of our recent studies (8). The expression con-
structs for V5-tagged Tau and its mutant formwere generously
provided by Dr. Michael Hutton.
Cell Culture, Transfection, and Pull-down Assays—COS-7 or
Neuro2A cells were grown in Dulbecco’s modified Eagle’s
medium (Sigma) supplemented with 10% (v/v) fetal calf serum,
100 units/ml penicillin, and 100 g/ml streptomycin. All cells
were grown at 37 °C in 5% CO2. Transfections were performed
using Lipofectamine 2000 transfection reagent (Invitrogen)
according to the manufacturer’s protocol. Neuro2A cells were
differentiated into neurons by culturing them in 1% fetal bovine
serum as described (21). To establish the physical interaction
between laforin and Tau proteins, we used the expression con-
struct that code for polyhistidine-tagged Tau (22). Lysates of
cells that had expressed His-tagged Tau with desired protein
were incubated with Ni2-affinity resin (Sigma) for 2 h at 4 °C
and processed for pull-down assays as recommended by the
manufacturer. Pulled down products were detected by immu-
noblotting using specific antibodies.
In Vitro Dephosphorylation Assay—The histidine-tagged
Tau protein, transiently overexpressed in COS-7 cells, was
hyperphosphorylated by treating the cells with wortmannin
and affinity-purified using nickel resins. Similarly, the His-
tagged laforin or its mutant Q293L was expressed and purified
as described (23). The nickel resin-bound Tauwasmixed with
wild-type laforin or its mutant in the phosphatase assay
buffer (50 mM HEPES, pH 6, 50 mM NaCl, 5 mM EDTA, 50
mM -mercaptoethanol) and incubated for 2 h at 37 °C. A
control reaction was performed in parallel, wherein the Tau
protein was incubated with nickel resins treated with cell
lysates that did not express His-tagged laforin. The reaction
products were finally mixed with SDS sample buffer, boiled,
and analyzed by immunoblotting.
Immunoprecipitation—Tissue or cell lysates were preincu-
bated with protein G-Sepharose (Bangalore Genei, India) for
2 h at 4 °C and then incubated with anti-laforin or anti-GSK3
antibody (as indicated) for 1 h at 4 °C. After incubation, protein
G-Sepharose was used for precipitation. The beads were
washed with lysis buffer four times and then eluted with SDS
sample buffer for immunoblot analysis as described (24).
GSK3 Activity Assay—GSK3 activity was measured as
described previously (25) after immunoprecipitation of GSK3
from 100 g of protein. Immobilized immune complexes were
washed twice with lysis buffer and twice with kinase reaction
buffer and incubatedwith phosphoglycogen synthase peptide-2
substrate (Upstate Biotechnology) and [-32P]ATP for 30 min
at 30 °C. After this incubation, an aliquot of samples was placed
on phosphocellulose disc (Whatman 31ET CHR filter paper),
air-dried, andwashed three times in 0.75% phosphoric acid and
once with acetone. Radioactivity in the phosphocellulose disc
was counted in a -counter (PerkinElmer Life Sciences).
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Immunoblotting Analysis—Protein samples were run on a
10% SDS-PAGE and transferred onto a nitrocellulose filter
(MDI, India) as described previously (7, 8). Signal intensity of
the immunoblot was quantitated using NIH Image software
(ImageJ; National Institutes of Health).
RESULTS
The characterization of laforin-deficient mice was reported
in one of our previous publications (15). The present investiga-
tionwas carried out on theC57BL/6 isogenic line for theEpm2a
gene knock-out, derived by back-crossing the F1 heterozygous
mutantswithC57BL/6 animals through 11 generations, and the
animals were genotyped as described (15).
Neurofibrillary Tangles Observed in Laforin-deficient Mice—
Our investigations on the neuropathological changes in the
brain sections of the 10-month-old laforin-deficient mice have
suggested the presence of neurofibrillary tangles (NFTs), as
revealed by Bielschowsky’s silver staining (Fig. 1, A–C). This
was subsequently confirmed by immunohistochemical staining
with antibodies E178 (26) and AT8 (27, 28) that specifically
recognize Tau protein phosphorylated at Ser396 or Ser202 resi-
dues, respectively (Fig. 1, D–I). Numerous neurons that were
positive for the dyes or the phospho-Tau antibodies were seen
primarily in the hippocampus, thalamus, cerebral cortex, cere-
bellum, and brain stem of the laforin-deficient mice but not in
the corresponding regions of the wild-type littermates (Fig. 1,
A–I). Identical observations were made with antibodies CP13
and PHF1 as well (supplemental Fig. S1, A–D). The NFTs in
laforin-deficient mice also stained intensely with ubiquitin
antibody (supplemental Fig. S1, E–G). NFTs were not observed
in the 2-, 4-, or 6-month-old knock-out mice analyzed.
In addition to brain, Tau protein is known to express inmuscle
tissues (29, 30). We have therefore checked for the presence of
hyperphosphorylation of Tau protein in the muscle tissues of the
10-month-old laforin-deficient mice. Phospho-Tau-specific anti-
bodies identified immunoreactive cytoplasmic inclusions in the
muscle sections from the knock-out mice but not the wild-type
littermates (Fig. 1, J–M). Such inclusionswerenot seen in themus-
cle sections of 4- and 6-month-old knock-out mice.
Biochemical and Ultrastructural Characterization of Tau in
Laforin-deficient Mice—Consistent with the immunohisto-
chemical observations, immunoblot analysis of Tau protein
from the 10-month-old animals showed a significant increase
in the phosphorylation levels at the Ser202 and Ser396 positions,
both inmuscle and brain tissues of the laforin-deficientmice, as
compared with the wild-type littermates (Fig. 2, A and B, and
supplemental Fig. S2A). This difference, however, was not obvi-
ous in the 4-month-old mice (Fig. 2A). The phosphorylation
levels of Tau were nearly the same in wild-type and heterozy-
gous animals of the 10-month age group (supplemental Fig.
S2C). Because Tau is known to form insoluble aggregates upon
hyperphosphorylation (31, 32), we further assessed the amount
of Tau in the Sarkosyl-insoluble fractions derived from the
brain and muscle tissues of the 10-month-old animals. A large
amount of insoluble and phosphorylated forms of Tau was
recovered from the brain and muscle tissue lysates of the
laforin-deficient mice as compared with lysates of wild-type
littermates (Fig. 2C). The Sarkosyl-insolublematerial recovered
from the laforin-deficient mice was further investigated with
transmission electron microscopy. The NFTs observed in the
Sarkosyl-insoluble fraction appeared to be straight filaments of
about 10–20 nm in diameter (Fig. 2D). Labelingwith antibodies
against phosphorylated Tau (Ser396) revealed reasonably abun-
dant Tau-containing filaments in the preparation (Fig. 2, E and
F). Such filaments were not seen in the preparations obtained
from the age-matched wild-type littermates (data not shown),
and the gold particles were not seenwhen the primary antibody
was omitted for the immunodetection for the samples from the
knock-out mice (data not shown). Taken together, the bio-
chemical and ultrastructural analyses strongly suggest the pres-
ence of NFT-like Tau aggregates in the brain and muscle tissue
of the laforin-deficient mice.
Changes in the Phosphorylation Status of Tau Kinases and
Tau Phosphatases in Laforin-deficient Mice—Having estab-
lished the difference in the phosphorylation levels of Tau pro-
FIGURE 1. Histochemical and immunohistochemical assessment of the
brain andmuscle sections from the wild-type and the Epm2a knock-out
mice. Shown is Bielschowsky’s silver staining in the brain stem region of the
10-month-old wild-type (A) and the Epm2a knock-out mice brains (B and C),
revealing neurofibrillary tangles. Shown are anti-Tau (E178 and AT8) immu-
noreactivity in the brain stem regions of the brain (D–I) or the skeletal muscle
tissues (J–M) of the 10-month-old wild-type (D, G, J, and L) and the Epm2a
knock-out mice, as indicated (E, F, H, I, K, andM). Scale bar, 30m in A, B, D, E,
G, and H; 10 m in C, F, and I; 20 m in J–M.
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tein in laforin-deficient mice, we next explored whether loss of
laforin leads to changes in the phospho forms of key kinases and
phosphatases that are known to regulate Tau. For this analysis,
we have selected six kinases and two phosphatases (see Fig. 3).
Activation of GSK3 is known to phosphorylate Tau protein
(33, 34). The active and inactive forms of GSK3 were quanti-
tated by looking at the phosphorylation status of Tyr216 and
Ser9 residues by using antibodies that are specific to these two
phospho forms (35, 36) and also by enzymatic assays using a
substrate (Fig. 3, A and B). Although the total level of GSK3
was comparable among the wild-type and laforin-deficient ani-
mals, the levels of the inactive form of GSK3 (phospho-Ser9)
were found to be significantly lower in the muscle and brain
tissues of the 10-month-old knock-out mice (Fig. 3, A and D,
and supplemental Fig. S2B).We thereforemeasured theGSK3
activity by 32P labeling in an in vitro assay and found that the
GSK3 from laforin-deficient mice indeed show increased
activity as compared with that from age-matched wild-type
mice (Fig. 3B). No difference in the phosphorylation levels of
Tyr216 residue was observed in the analyzed tissues of the two
age groups (Fig. 3A).
Using a similar approach, we next examined how a few other
regulators (kinases/phosphatases) might contribute to hyper-
phosphorylation of Tau protein in laforin-deficient mice. As
shown in Fig. 3C, levels of CDK5 and its active form (CDK5-P),
PKA and its active form (PKA-P), protein kinase B (AKT) and
its active form (AKT-P), PP2A and
its active form (PP2A-P), and the
total levels of PP1 were found to be
similar among the wild-type and
the knock-out mice littermates
of the 10-month age group. Taken
together, these results suggest that
the contributions of these enzymes
to Tau phosphorylation were not
affected by the loss of laforin.
Laforin Physically Interacts with
and Dephosphorylates the Tau
Protein—Since the loss of laforin
led to the hyperphosphorylation of
Tau, we next explored the possi-
bility that laforin, being a protein
phosphatase, directly interacts
with and dephosphorylates Tau.
For this, polyhistidine-tagged Tau
was transiently coexpressed with
green fluorescent protein (GFP)-
tagged laforin or GFP in COS-7
cells, and lysates were analyzed by
nickel affinity bead pull-down
assays. As can be seen in Fig. 4,
Tau was able to pull down GFP-
laforin and not the GFP, thus
establishing the specific and phys-
ical interaction between laforin
and Tau proteins. We next deter-
mined the domain of laforin that
interacted with Tau. For this, we
created constructs that code for either the CBD or the DSPD
of the laforin protein with the FLAG tag at the amino termi-
nal (see Fig. 4C). His-tagged Tau was coexpressed with
FLAG-tagged full-length laforin or its truncated forms (CBD
or the DSPD) in COS-7 cells and processed for nickel affinity
pull-down assays. As shown in Fig. 4B, Tau was able to pull
the full-length laforin and the DSPD of laforin, but the trun-
cated peptide having the CBDwas not detected in the pulled-
down products, suggesting that laforin interacts with Tau
through its phosphatase domain. We have also checked the
interaction between endogenous Tau and laforin using a co-
immunoprecipitation approach. For this, we have used the
brain tissue lysates from 10-month-old animals, pulled
laforin using anti-laforin antibody, and checked for the pres-
ence of Tau protein in the pull-down products. As shown in
Fig. 4D, Tau was detected in the pulled-down product from
the wild-type tissue and not in the tissues from the laforin-
deficient mice, confirming the interaction between laforin
and Tau proteins and the specificity of the assay employed.
Having confirmed a direct physical interaction between
laforin and Tau proteins, we next examined whether phos-
phorylated Tau is a substrate for laforin. For this, the wild-
type Tau was expressed either alone or with laforin or an
empty vector (control) in COS-7 cells and treated with wort-
mannin, a known inducer for Tau hyperphosphorylation
(37). Similarly, a Tau missense mutant (P301L), which is
FIGURE2.Biochemical andelectronmicroscopic analysesofTauprotein in laforin-deficientmice.A, brain
and muscle tissue lysates of 4- (4 MO) or 10-month-old (10 MO) Epm2a knock-out (KO) or the wild-type (WT)
littermates were evaluated by using antibodies that detect changes in the phospho form (CP13 and PHF1) or
the total formof Tau protein (TGF5) by immunoblotting, as indicated. B, bar diagram showing the difference in
the signal intensity of different forms of Tau, as indicated. Each bar represents average values S.D. of immu-
noblot analyses (n  4; **, p  0.005). C, the detergent-insoluble Tau from brain and muscle tissues of
10-month-old animals were immunoblotted with (CP13, PHF1, and TGF5) antibodies raised against distinct
forms of Tau, as indicated. D, electron microscopic analysis of Sarkosyl-insoluble NFTs isolated from the
10-month-old laforin-deficient mice as revealed by negative staining with 2% uranyl acetate. Most NFTs
appeared to be straight filaments. E, purified NFTs were immunolabeled with an antibody against the Ser396
phospho-Tau, followed by negative staining with phosphotungstic acid. The phospho-Tau antibody was
detected with a 10-nm gold particle-conjugated secondary antibody. Scale bar, 50 nm.
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known to become hyperphosphorylated when overexpressed
(31), was expressed either alone or with laforin. As shown in
Fig. 5A, coexpression of laforin resulted in a significant
reduction in the cellular levels of Ser396 phospho form of
both wild-type and the mutant Tau. Similarly, knockdown of
laforin in a differentiated neuroblastoma cell line (Neuro2A)
led to increased phosphorylation at the Ser396 residue of
endogenous Tau (Fig. 5B). To finally confirm that Tau is
indeed a direct substrate of laforin, hyperphosphorylated
Tau was purified and incubated with wild type or the mutant
form of laforin, and the phosphorylation status at Ser396 res-
idue of Tau was evaluated by immunoblotting. Incubation of
wild-type laforin with hyperphosphorylated Tau showed a
significant reduction in the phosphorylation level at the
Ser396 residue as compared with reactions with the mutant
laforin or the mock control (Fig. 5, C and D). These in vitro
studies, in addition to replicating the findings in the laforin-
deficient mice, have established that laforin indeed dephos-
phorylates the Ser396 residue of Tau, and thus it is a Tau
phosphatase. Knockdown of laforin or its overexpression did
not alter the phosphorylation status of GSK3 at the Ser9
position in the Neuro2A cell line (supplemental Fig. S2,
D–E), suggesting that the observed difference in the phos-
phorylation status of GSK3 in the laforin-deficient mice
could be a secondary effect and could be due to the physio-
logical changes associated with loss of laforin in mice.
FIGURE 3. Changes in kinases and phosphatases that regulate Tau phos-
phorylation. A, lysates of brain andmuscle tissues of 4- (4 MO) or 10-month-
old (10 MO) Epm2a knock-out (KO) or wild-type (WT) littermates were ana-
lyzed with immunoblotting and antibodies against Ser9 phospho-, Tyr216
phospho-, or total form of GSK3, as indicated. B, GSK3 activity assay was
done on the brain and muscle tissue of the 10-month-old Epm2a knock-out
(KO) or wild-type (WT) littermates. The bar diagram shows the difference in
the relative activity of GSK3, as indicated. Each bar represents average val-
ues S.D. (n 4; **, p 0.005).C, similarly, lysates from the brain andmuscle
tissues of the 10-month-old animalswere tested for the following Tau kinases
and phosphatases: Ser473 phospho-AKT (AKT-P), total AKT, Ser159 phospho-
CDK5 (CDK5-P), total CDK5, Ser96 phospho-PKA (PKA-P), total PKA, Tyr307
phospho-PP2A (PP2A-P), total PP2A, and total PP1 antibodies.D, bar diagram
showing the difference in the signal intensity of bands detected by antibody
specific to phospho-GSK3 in the brain and muscle tissues in the 10-month-
old animals. Each bar represents average values S.D. (n 4; **, p 0.005).
FIGURE 4. Laforin physically interacts with Tau protein. A, V5/His-tagged
Tau was coexpressed with GFP-laforin or with GFP in COS-7 cells and pro-
cessed for thepull-downassayusing thenickel affinity resin. Thepulleddown
products (PD) and whole cell lysates (WCL) were immunoblotted (IB) and
probed with anti-GFP antibody and anti-V5 antibody. B, the phosphatase
domain of laforin interacts with Tau protein. V5/His-tagged Tau protein was
coexpressed inCOS-7 cellswith FLAG-tagged laforin, theCBDof laforin, or the
DSPD and processed for the pull-down assay using the nickel affinity resin.
The pulled down products and whole cell lysates were immunoblotted and
probed with anti-FLAG and anti-V5 antibodies, as indicated. COS-7 cells that
expressed FLAG-laforin only were processed for pull-down assay as control.
As expected, anti-FLAG antibody did not detect any peptide in the pull-down
product of this assay (last lane). C, schematic showing the domain organiza-
tion of laforin protein and its truncated forms used for the pull-down assays.
The amino-terminal triangles represent the FLAG epitope.D, co-immunopre-
cipitation analysis demonstrating the interaction between endogenous
laforin and Tau proteins. Tissue lysates from 10-month old brain of
wild-type (WT) or Epm2a knock-out mice (KO) were processed for immuno-
precipitationwith a rabbit polyclonal anti-laforin antibody, and the immuno-
precipitatedproducts (IP)were immunoblotted (IB)with ananti-Tauantibody
raised in mice. Whole tissue lysates (input) were used as control. Note the
presence of an66 kDa Tau band (identified with an arrow) in the immuno-
precipitated products in the tissue lysate from thewild-type but not from the
knock-out mice.
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DISCUSSION
In this report, we demonstrate that the loss of laforin leads to
accumulation of hyperphosphorylated Tau as NFTs in the LD
mice model. The observed NFTs were ubiquitinated and deter-
gent-insoluble, as known in Alzheimer disease (18, 38, 39), and
such forms were abundant in the 10-month-old knock-out mice,
suggesting a progressive deterioration of brain function. The
regions that were positive for the NFTs strongly correlated with
the sites of laforin expression (40). NFTs were not seen in the
heterozygote littermates, suggesting that the complete loss of
laforin is required for its formation inLD.Curiously, Lafora bodies
and neuronal cell death, the other two neuropathological changes
observed in the knock-outmice, predate the NFT formation (15–
17).Thus, theprogressiveonsetof theLD-like symptomsobserved
in laforin-deficient mice seems to correlate well with the age-de-
pendentdepositionofNFTs in thebrain (15).NFTshave alsobeen
reported in LD patients (41); thus, abnormal regulation of Tau
protein appears to be one of the common neuropathological
changes associatedwithLD inhumansandmice. Intriguingly,Tau
straight filaments have also been described in Alzheimer and Pick
diseases (42, 43). Thus, the NFTs are likely to underlie a subset of
symptoms of LD, like dementia, which is known in tauopathies as
well (2).
One of the significant findings of the present study was the
observation of NFTs in the muscle tissues of the laforin-defi-
cient mice. NFTs in the skeletal muscle are known in several
forms ofmyopathies that are characterized by progressivemus-
cle weakness and atrophy (44, 45). Although muscular atrophy
is known in human LD (2), inclusions other than Lafora bodies
in muscle have not yet been reported. Pending such findings,
our present set of observations, together with our earlier report
on muscular weakness in this LD mouse model (15), suggest
that the Tau-positive inclusions could underlie some of the def-
icits of muscle functions seen in LD.
In determining which kinase or phosphatase is involved in the
hyperphosphorylation of Tau in laforin-deficient mice, we show
here that the level of the Ser9-phospho (inactive) form of GSK3
was lower in the 10-month-old knock-out mice. However, no
changes in the level of the protein or in the phosphorylation levels
were observed for several other players that are known to regulate
the phosphorylation of Tau protein. Thus, the overactive GSK3
could be one of the triggers for the formation ofNFTs in LDmice.
Our observations on the GSK3 phosphorylation in the laforin-
deficient mice and in cellular models contradict the report of
Wang et al. (46) that the Ser9 residue of GSK3 was dephospho-
rylated by laforin phosphatase and support an earlier report that
GSK3 is not a substrate of laforin (11). Since there is a reduction
in the phospho form of GS3K in the knock-out mice, laforin
probably acts upstream of this key enzyme. AKT, PKA, and PP1
are a fewof theknownregulators of theSer9 residueofGSK3 (36,
48, 49), and all three of them did not show a significant change in
the phosphorylation level in the laforin-deficient mice. It would
thereforebeof interest to look forother regulatorsofGS3K in the
laforin-deficient mice.
Because laforin is a dual specificity phosphatase (4), we have
also tested the possibility whether Tau could be a substrate for
laforin.Wedemonstrate here that laforin physically interactswith
Tau and that the interaction could perhaps be limited to the phos-
phatase domain of laforin. Consistent with the findings in the
laforin-deficient mice, we show here with cellular models that
coexpressionof laforinwithTaudecreases thephospho-Tau levels
and that knockdown of laforin leads to an increase in the phospho
form of Tau. Direct evidence for laforin being a Tau phosphatase
came from the in vitro dephosphorylation assay. Thus, laforin
might dephosphorylate Tau, at least at the Ser396 residue, under
appropriatephysiological signals.Mutations resulting in the lossof
laforin, its phosphatase activity, or its interaction with Tau would
lead to hyperphosphorylation of Tau and theNFTs, as seen in the
LD mice. It would be of much interest now to check the level
and/or activity of laforin in tauopathies like Alzheimer disease.
Tau phosphorylation reflects a critical balance between Tau
kinase and Tau phosphatase activities. We show here that loss of
laforin is associated with an increase in the levels of active form of
GSK3 in the LD model. Thus, NFTs in LD may both involve
activationof theTaukinase (GSK3) and the inactivationof aTau
phosphatase (laforin). GSK3 is known to act on Tau either indi-
vidually or as a complex in the Alzheimer disease condition (35,
50). The activation of GSK3 in LD draws striking parallels with
Alzheimer disease. Another element for Tau pathology in LD
couldbe theLaforapolyglucosanbodies.Alterations in theglucose
metabolism are associated with abnormal Tau phosphorylation
(47, 51). Lafora bodies are thought to result from abnormal glyco-
gen metabolic pathways (1, 11, 15, 16); therefore, a role for these
inclusions in the genesis of NFTs cannot be ruled out.
In summary, we demonstrate here that loss of laforin leads to
Tau hyperphosphorylation andNFTs, that laforin could be a crit-
FIGURE5.LaforindephosphorylatesTauproteinat Ser396 residue.A, wild-
type Tau or itsmutant (P301L) was coexpressedwith a construct for laforin or
an empty vector in COS-7 cells and analyzed for the difference by immuno-
blotting with PHF1 antibody, as indicated. COS-7 cells expressing wild-type
Tau were treated with wortmannin to induce hyperphosphorylation of Tau.
B, Neuro2A cellswere transfectedwith empty vector (vector; lanes 1 and 2), or
the short hairpinRNA interference construct to silence the Epm2agene (RNAi-
Epm2a; lanes 3 and 4), differentiated into neurons, and analyzed for changes
in the phospho form of endogenous Tau by immunoblotting with PHF1. The
efficiency of Epm2a knockdown was previously established by immunoblot-
ting with anti-laforin antibody (8). C, Tau, laforin, and laforin mutant were
overexpressed in COS-7 cells, affinity-purified, and used for the in vitro
dephosphorylation assay as indicated. Resins incubated with empty vector
transfected (pcDNA) cells were used as control. The reactionwas arrested and
immunoblotted with antibodies as indicated, as discussed under “Experi-
mental Procedures.” D, bar diagram showing the difference in the signal
intensity of bands detected by PHF1 antibody in the in vitro dephosphoryla-
tion assays donewith the wild-type laforin, its mutant (Q293L), or the control
resin (pcDNA). Eachbar represents averagevaluesS.D. (n3; **,p0.005).
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ical regulator of Tau phosphorylation, and that the abnormal
hyperphosphorylation of Tau might underlie some of the symp-
toms in LD. This study thus provides novel insight into the
molecular basis of LD and has important implications on the
formation of NFTs in tauopathies.
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Supplemental Data: 
Legend to supplemental figures (Fig. S1 and S2) 
Figure S1: Tau protein immunoreactivity in the brain and muscle sections from wild-type 
(WT) and the Epm2a knockout (KO) mice. A-D Immunoreactive tau species, specific 
to phosphorylation dependent antibodies PHF1 and CP13 raised in mouse against the 
Ser396 or Ser202 phospho-tau, in the brains sections of Epm2a knockout (B, D) and 
not in the wild-type animals (A, C). Double immunofluorescence staining for PHF1 
and ubiquitin in the 10 MO Epm2a knockout mice brain sections (E, G). The green 
(E) and red (F) signals identify tau and ubiquitin, respectively, and the yellow signals 
(G) reveal their co localization (merged image). Image H represent a control reaction 
for the knockout mice muscle section, where in the primary antibody was omitted. 
Scale bar: 10 µm in A, B, C and D; 30 µm in E, F and G.; 20 µm in H.  
Figure S2: (A) Brain and muscle tissue lysates of 10-month-old (10 MO) Epm2a knockout 
(KO) or the wild-type (WT) littermates were evaluated by using antibodies that detect 
changes in the phospho- (CP13 and PHF1), or the total form of tau protein (TGF5) by 
immunoblotting, as indicated. (B) Lysates of brain and muscle tissues of 10-month-old 
Epm2a knockout (KO) or wild-type (WT) littermates were analyzed with immunoblotting and 
antibodies against Ser9 phospho-, Tyr216 phospho- or total form of GSK3β, as indicated. (C) 
Muscle tissue lysates of 10-month-old (10 MO) of wild-type (WT) and heterozygous 
(HT) littermates for the Epm2a knockout allele were evaluated by using antibodies 
that detect changes in the phospho forms of tau protein (antibody CP13 and PHF1) by 
immunoblotting, as indicated. (D) Neuro2A cells were transfected with either the 
empty vector or with a shRNA construct for the RNAi-mediated knockdown of the 
Epm2a transcripts, and the cell lysates immunoblotted for the detection of phospho or 
total form of GSK3β and laforin as indicated. (E) Neuro2A cells were transiently 
transfected with empty vector (pcDNA), vector expressing wild-type laforin (WT) or 
its dominant negative mutant (C266S), and the lysate were probed with antibodies that 
detect the Ser9 phospho form, all forms GSK3β or the Myc epitope as indicated. 
 
Supplementary figure S1:
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